ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC

被引:4
|
作者
Chan, Sze Ling [1 ]
Low, Joshua Jun Wen [2 ]
Chia, Kee Seng [1 ,3 ,4 ,5 ,6 ]
Wee, Hwee-Lin [2 ,7 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore
[3] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[5] Genome Inst Singapore, Singapore, Singapore
[6] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore
[7] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore
关键词
Warfarin; Pharmacogenetic testing; Attitudes; Asian; ADVERSE DRUG-REACTIONS;
D O I
10.1017/S026646231300069X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Genetic factors affecting warfarin maintenance dose have been well established, but patient acceptance is a necessary consideration for the successful clinical implementation of warfarin pharmacogenetic testing (WPGT). In this study, we aimed to determine the attitudes toward WPGT among Singaporean Chinese. Methods: A total of 194 warfarin patients and 187 members of the public completed a structured survey on paper and the Internet, respectively. Attitudes were expressed as willingness to undergo WPGT (single item with 5-point response) and expectations and concerns about WPGT (two multi-item scales). Relationships between attitudes and socio-demographic and clinical variables were explored using Fisher's exact test, Student's t-test, one-way analysis of variance or Pearson's correlation. Results: Majority of respondents were willing to or neutral about undergoing WPGT. Both patients and public had relatively high expectations (mean [SD]: 3.77 [0.63], and 3.97 [0.55], respectively) and moderately high concerns (mean [SD]: 3.30 [0.69] and 3.33 [0.68], respectively) about WPGT. Willingness to undergo WPGT was associated with gender, educational status, length of warfarin treatment, and number of chronic diseases among warfarin patients, and with history of adverse drug reactions and number of chronic diseases among the public. Higher expectation of WPGT was associated with higher willingness (p < .001 in both populations), while higher concern was associated with lower willingness to undergo WPGT among the public (p = .004) but not among patients (p = .072). Conclusion: Patient acceptance is not a major barrier to clinical implementation of WPGT but patient education is necessary and the ethical, social, and legal issues should be addressed.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [41] Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
    Kirsten Neudoerffer Kangelaris
    Stephen Bent
    Robert L. Nussbaum
    David A. Garcia
    Jeffrey A. Tice
    Journal of General Internal Medicine, 2009, 24 : 1358 - 1358
  • [42] Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
    Kangelaris, Kirsten N.
    Bent, Stephen
    Nussbaum, Robert L.
    Garcia, David A.
    Tice, Jeffrey A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 29 (02) : 258 - 258
  • [43] Pharmacogenetic Warfarin Dosing Algorithms: Validity in Egyptian Patients
    Selim, Tarek E.
    Azzam, Hanan A.
    Ghoneim, Hayam R.
    Mohamed, Ahmed A.
    El Wakeel, Hossam
    Abu Bakr, Helmy M.
    ACTA HAEMATOLOGICA, 2018, 139 (04) : 255 - 262
  • [44] Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
    Kangelaris, Kirsten Neudoerffer
    Bent, Stephen
    Nussbaum, Robert L.
    Garcia, David A.
    Tice, Jeffrey A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (05) : 656 - 664
  • [45] Q: Should we use pharmacogenetic testing when prescribing warfarin?
    Rouse, Mary
    Cristiani, Cari
    Teng, Kathryn A.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2013, 80 (08) : 483 - 486
  • [46] International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing
    Pereira, Naveen L.
    So, Derek
    Bae, Jang-Ho
    Chavez, Ivan
    Jeong, Myung Ho
    Kim, Sang Wook
    Madan, Mina
    Graham, John
    O'Cochlain, Fearghas
    Pauley, Nicole
    Lennon, Ryan J.
    Bailey, Kent
    Hasan, Ahmed
    Baudhuin, Linnea M.
    Bell, Malcolm R.
    Lerman, Amir
    Goodman, Shaun
    Mathew, Verghese
    Farkouh, Michael
    Rihal, Charanjit S.
    PHARMACOGENETICS AND GENOMICS, 2019, 29 (04): : 76 - 83
  • [47] A systematic review of pharmacogenetic testing in primary care: Attitudes of patients, general practitioners, and pharmacists
    Hansen, Johanne Molby
    Norgaard, Josefine D. S. V.
    Sporrong, Sofia Kalvemark
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2022, 18 (08): : 3230 - 3238
  • [48] Patient Attitudes toward Receiving Chemotherapy and Pharmacogenetic Testing in Curative and Palliative Cancer Patients
    Cuffe, Sinead
    Hon, Henrique
    Tobros, Kimberly
    Wong, Chung-Kwun Amy
    De Souza, Bradley
    McFarlane, Graham
    Masroor, Sohaib
    Hasani, Ekta
    Sun, Bin
    Di Tommaso, Natalie
    Xu, Wei
    Leighl, Natasha
    Alibhai, Shabbir
    Issa, Amalia
    Liu, Geoffrey
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S327 - S328
  • [49] A SHORT REVIEW OF THE PROFESSIONALS AND GENERAL PUBLIC ATTITUDES AND CONCERNS ABOUT PHARMACOGENETIC TESTING WITH THE RECOGNITION OF THE PHARMACISTS ROLE
    Krajnovic, Dusanka M.
    Levic, Marija M.
    Taerel, Adriana-Elena
    FARMACIA, 2018, 66 (05) : 770 - 777
  • [50] International Survey of Patients Undergoing Percutaneous Coronary Intervention and Their Attitudes Towards Pharmacogenetic Testing
    Pereira, Naveen L.
    So, Derek
    Bae, Jang-Ho
    Chavez, Ivan
    Jeong, Myung Ho
    Kim, Sang Wook
    Madan, Mina
    Graham, John
    O'Cochlain, Fearghas
    Pauley, Nicole
    Lennon, Ryan
    Bailey, Kent
    Hasan, Ahmed
    Baudhuin, Linnea
    Bell, Malcolm
    Lerman, Amir
    Goodman, Shaun
    Mathew, Verghese
    Farkouh, Michael
    Rihal, Charanjit
    CIRCULATION, 2018, 138